{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-23-006600","form_type":"8-K","ticker":"SANA","cik":"0001770121","company_name":"Sana Biotechnology, Inc.","filed_at":"2023-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.476478+00:00","generated_at":"2026-06-16T06:38:50.583813+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Sana Biotechnology announces departure of Sunil Agarwal as EVP, Head of Development and CMO","bullets":["Separation effective April 28, 2023; Sunil Agarwal to provide transition services under a Transition Agreement.","Severance of $560,523 (9 months base salary plus pro-rata bonus) plus COBRA coverage for up to 9 months.","Acceleration of 89,377 unvested stock options; exercise period extended to December 31, 2023.","Consulting Agreement at $256/hour, effective April 29, 2023, ending May 12 or extended to May 26, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-23-006600","json":"https://secwatch.observer/filing/0001564590-23-006600.json","markdown":"https://secwatch.observer/filing/0001564590-23-006600.md","text":"https://secwatch.observer/filing/0001564590-23-006600.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770121/000156459023006600/0001564590-23-006600-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770121/000156459023006600/sana-8k_20230428.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T06:38:50.583813+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"be777a8f42","claim":"Sunil Agarwal resigned as Executive Vice President, Head of Development, and Chief Medical Officer at Sana Biotechnology, Inc..","evidence_excerpt":"Sana Biotechnology, Inc. (the “Company”) previously filed a Current Report on Form 8-K disclosing the resignation of Sunil Agarwal, M.D. as the Company’s Executive Vice President, Head of Development, and Chief Medical Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1770121/000156459023006600/0001564590-23-006600-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Executive Vice President, Head of Development, and Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}